Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada

(1) Background: Bispecific antibodies (BsAbs) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) can be delivered in ambulatory healthcare settings; however, the safe and effective management of potential side effects, such as cytokine release syndrome (CRS), requires...

Popoln opis

Bibliografske podrobnosti

Principais autores:	David MacDonald, Robert Puckrin, Pamela Skrabek, Selay Lam, Jai Jayakar, Isabelle Fleury, Christopher Lemieux, Mélina Boutin, Jacqueline Costello
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-08-01
Serija:	Current Oncology
Teme:	diffuse large B-cell lymphoma bispecific antibodies T-cell engaging therapy relapsed refractory lymphoma epcoritamab glofitamab
Online dostop:	https://www.mdpi.com/1718-7729/32/8/460
Oznake:	Označite Brez oznak, prvi označite!